# drug development (audio feeds) — RSS Amplifier Recent posts from the 2 feeds in the RSS Amplifier directory that cover drug development. Page: Feed: --- ## [Issue 46 — Spray-Dried Dispersions](https://soundcloud.com/the-altascientist/issue-46-spray-dried-dispersions) _2025-10-10 · Altasciences_ In this issue, we examine spray-dried dispersions (SDDs) as an effective method to improve solubility and bioavailability of your active pharmaceutical ingredient (API) in early-phase drug development. We review the spray drying process, which converts a liquid into a dry powder, and how the resulting SDDs benefit from improved characteristics for further development. We also discuss the… [Listen](https://feeds.soundcloud.com/stream/2187225278-the-altascientist-issue-46-spray-dried-dispersions.mp3) ## [Issue 45 — Discovery Studies: An Agile Approach to Early Data for Quicker Decisions](https://soundcloud.com/the-altascientist/issue-45-discovery-studies-an-agile-approach-to-early-data-for-quicker-decisions) _2025-10-10 · Altasciences_ In this issue, we explore the characteristics and advantages of non-GLP discovery studies, along with emerging trends in this important early phase of drug development research. We also present two case studies from our Sacramento site, highlighting discovery studies that assessed the biodistribution of the test article under specific experimental conditions. [Listen](https://feeds.soundcloud.com/stream/2187222058-the-altascientist-issue-45-discovery-studies-an-agile-approach-to-early-data-for-quicker-decisions.mp3) ## [Issue 44 — The Importance of Cytokine Release Assays to Derisk the Development of Immunomodulatory Drugs](https://soundcloud.com/the-altascientist/issue-44-the-importance-of-cytokine-release-assays-to-derisk-the-development-of-immunomodulatory-drugs) _2025-10-10 · Altasciences_ In this issue of The Altascientist, we review strategies, including those implemented at Altasciences, for developing, qualifying, and implementing CRAs to assess the safety of test articles in vitro to complement in vivo preclinical safety assessment. [Listen](https://feeds.soundcloud.com/stream/2187219473-the-altascientist-issue-44-the-importance-of-cytokine-release-assays-to-derisk-the-development-of-immunomodulatory-drugs.mp3) ## [Your Story, Our Science: Her ALS Story and ALS TDI Bring Together Science and Lived Experience](https://omny.fm/shows/endpoints-podcast/your-story-our-science-her-als-story-and-als-tdi-bring-together-science-and-lived-experience) _2025-09-05 · Endpoints_ Nobody knows ALS better than people living with the disease. Therefore, it's crucial for scientists to utilize the perspectives of people with lived experience in their research. Earlier this year, ALS TDI joined with Her ALS Story -a group of women diagnosed with ALS before the age of 35-to put on a series of Town Hall webinars that highlighted the importance of this connection. The three-part… [Listen](https://traffic.omny.fm/d/clips/0d2f442e-125e-4a95-9e25-aabd01618751/7415a69a-125b-4d75-afeb-aabe01348187/d9ebdda9-c96d-4422-991d-b34f010b7e16/audio.mp3?utm_source=Podcast&in_playlist=96a50e82-8316-4028-8520-aabe01364b80) ## [How Brain Computer Interfaces (BCIs) Could Help People with ALS Communicate](https://omny.fm/shows/endpoints-podcast/how-brain-computer-interfaces-bcis-could-help-people-with-als-communicate) _2025-08-14 · Endpoints_ Brain-computer interfaces, or BCIs, aim to enable people to control various adaptive devices directly with their thoughts. There are many BCI devices currently in various stages of development, with the potential to help people with ALS and similar conditions across many different activities of daily life. One particular area in which BCI devices may be able to support people with advanced ALS… [Listen](https://traffic.omny.fm/d/clips/0d2f442e-125e-4a95-9e25-aabd01618751/7415a69a-125b-4d75-afeb-aabe01348187/13d06a73-5551-4b2e-9b94-b33900fa48f4/audio.mp3?utm_source=Podcast&in_playlist=96a50e82-8316-4028-8520-aabe01364b80) ## [Issue 43 — Advancing Vision Care With Formulation and Manufacture of Ocular Therapeutics](https://soundcloud.com/the-altascientist/issue-43-formulation-and-manufacture-of-ocular-therapeutics) _2025-04-08 · Altasciences_ According to the World Health Organization, at least a billion people are currently living with vision impairment from a preventable or treatable source. The main conditions causing their distance vision impairment or blindness are cataracts, refractive error, age-related macular degeneration, glaucoma, diabetic retinopathy, and presbyopia. Precedence Research reports that the global ophthalmic… [Listen](https://feeds.soundcloud.com/stream/2074084436-the-altascientist-issue-43-formulation-and-manufacture-of-ocular-therapeutics.mp3) ## [The Power of Big Data in ALS: Dr. Danielle Boyce](https://omny.fm/shows/endpoints-podcast/the-power-of-big-data-in-als-dr-danielle-boyce) _2025-02-20 · Endpoints_ Today on Endpoints, Dr. Danielle Boyce joins us to explore how data science is transforming our understanding of ALS and why the ALS Research Collaborative (ARC) Study presents an exciting opportunity for research. As ALS TDI's Principal Investigator for Real-World Evidence , Dr. Boyce brings extensive expertise in analyzing big data to uncover key insights about ALS. Her work focuses on… [Listen](https://traffic.omny.fm/d/clips/0d2f442e-125e-4a95-9e25-aabd01618751/7415a69a-125b-4d75-afeb-aabe01348187/f1f5f42f-184f-4fe8-8ee6-b28a0111b51b/audio.mp3?utm_source=Podcast&in_playlist=96a50e82-8316-4028-8520-aabe01364b80) ## [So Much So Fast: Documenting the Earliest Days of ALS TDI](https://omny.fm/shows/endpoints-podcast/so-much-so-fast-documenting-the-earliest-days-of-a) _2025-01-16 · Endpoints_ 25 years ago, Steven Ascher and Jeanne Jordan began filming a documentary about a new, one-year-old organization and the family that founded it. That organization was called the ALS Therapy Development Foundation, and its mission was to find treatments for ALS. It was started by Jamie Heywood, whose brother Stephen had been diagnosed with the disease at the age of 29. The film they made, So Much… [Listen](https://traffic.omny.fm/d/clips/0d2f442e-125e-4a95-9e25-aabd01618751/7415a69a-125b-4d75-afeb-aabe01348187/2e2af068-71dd-4406-a7f8-b267011e9a0e/audio.mp3?utm_source=Podcast&in_playlist=96a50e82-8316-4028-8520-aabe01364b80) ## [The ALS Trial Navigator: Dr. Nadia Sethi on Building a Comprehensive Clinical Trial Database](https://omny.fm/shows/endpoints-podcast/the-als-trial-navigator-dr-nadia-sethi-on-building) _2024-12-13 · Endpoints_ In February 2024, ALS TDI launched the ALS Trial Navigator, a set of online tools designed to help people with ALS find clinical trials. Users can fill out a questionnaire to be matched with trials that meet their criteria, search a global database of studies, and even find sites close to them on an interactive map. Dr. Nadia Sethi, an ALS advocate who became a clinical trial expert after her… [Listen](https://traffic.omny.fm/d/clips/0d2f442e-125e-4a95-9e25-aabd01618751/7415a69a-125b-4d75-afeb-aabe01348187/6857d977-2861-4fd4-a161-b2450130abcd/audio.mp3?utm_source=Podcast&in_playlist=96a50e82-8316-4028-8520-aabe01364b80) ## [Issue 42 — Managing the Complexities of Glucagon -like Peptide-1 Receptor Agonist Drug Development](https://soundcloud.com/the-altascientist/issue-42-glucagon-like-peptide-1-receptor-agonist-drug-development) _2024-11-15 · Altasciences_ Current and future development of glucagon-like peptide-1 receptor agonists, more commonly referred to as GLP-1 RAs, or simply as GLP-1s, involves complexities not only in formulation but in all areas of early-phase drug development. Developing and refining preclinical models for early efficacy signals, developing and validating the bioanalytical assays necessary for quantitation, and designing… [Listen](https://feeds.soundcloud.com/stream/1959393479-the-altascientist-issue-42-glucagon-like-peptide-1-receptor-agonist-drug-development.mp3) ## [Your 24/7 AI Media Buyer (Sponsored)](https://crawlproof.com/a/zcEK0sKGZ0IY) _2024-11-14 · **Sponsored**_ Finds placement, geo, and funnel leaks and proposes fixes you approve ## [Chris Ritter of Oakland United Beerworks: An Ales for ALS™ Story](https://omny.fm/shows/endpoints-podcast/chris-ritter-of-oakland-united-beerworks-an-ales-f) _2024-11-14 · Endpoints_ Chris Ritter, the co-owner of Oakland United Beerworks, never thought he’d make a profession out of brewing. He had always loved beer but was a lawyer by training. Brewing was his son Andrew’s great passion. From a young age, Andrew always knew he wanted to make beer. After college, he got into the industry and eventually became the lead brewer of his own brewery. Everything changed for the Ritter… [Listen](https://traffic.omny.fm/d/clips/0d2f442e-125e-4a95-9e25-aabd01618751/7415a69a-125b-4d75-afeb-aabe01348187/352bddaa-1977-4006-a8a8-b228012a6f60/audio.mp3?utm_source=Podcast&in_playlist=96a50e82-8316-4028-8520-aabe01364b80) ## [Biogen's Dr. Stephanie Fradette on the Current State of ALS Research](https://omny.fm/shows/endpoints-podcast/biogens-dr-stephanie-fradette-on-the-current-state) _2024-10-30 · Endpoints_ We need more – likely many more – effective treatments to end ALS. Progress in ALS research has been too slow for too long but, in 2024, we’re witnessing significant advances and a new pace of progress. The past few years have see more treatments for ALS in clinical trials than ever before. Still, most drugs that reach trial fail, in any disease. However, the more experimental treatments that make… [Listen](https://traffic.omny.fm/d/clips/0d2f442e-125e-4a95-9e25-aabd01618751/7415a69a-125b-4d75-afeb-aabe01348187/46dc1d28-2a6c-4735-a919-b219013584ad/audio.mp3?utm_source=Podcast&in_playlist=96a50e82-8316-4028-8520-aabe01364b80) ## [ALS TDI's Early Years: Founding the First Nonprofit Biotech](https://omny.fm/shows/endpoints-podcast/als-tdis-early-years-founding-the-first-nonprofit) _2024-10-16 · Endpoints_ In 1999, Stephen Heywood, who was 29 years old at the time, was diagnosed with ALS. His family was devastated when they learned that there were no treatments that could slow or stop his disease. His brother Jamie decided that he had to do something about it, founding the organization that would eventually become ALS TDI – the world’s first nonprofit biotech – in the basement of his parents’… [Listen](https://traffic.omny.fm/d/clips/0d2f442e-125e-4a95-9e25-aabd01618751/7415a69a-125b-4d75-afeb-aabe01348187/645d99ac-2fb0-4950-b017-b20b01216182/audio.mp3?utm_source=Podcast&in_playlist=96a50e82-8316-4028-8520-aabe01364b80) ## [Issue 41 — Immunomodulation Assessments for Clinical Trials](https://soundcloud.com/the-altascientist/issue-41-immunomodulation-assessments-for-clinical-trials) _2024-09-20 · Altasciences_ Immunomodulatory drug development is trending toward increasingly complex modalities as science advances and more effective and safe immunotherapies are needed. Immunomodulatory drugs are at the forefront for the treatment of various types of cancer, infectious diseases, and numerous autoimmune diseases, including rheumatoid arthritis, type I diabetes, lupus, and multiple sclerosis. As the… [Listen](https://feeds.soundcloud.com/stream/1920507428-the-altascientist-issue-41-immunomodulation-assessments-for-clinical-trials.mp3)